These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 15938033)

  • 1. Targeting albumin excretion rate in the treatment of the hypertensive diabetic patient with renal disease.
    Krimholtz MJ; Karalliedde J; Thomas S; Bilous R; Viberti G
    J Am Soc Nephrol; 2005 Mar; 16 Suppl 1():S42-7. PubMed ID: 15938033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Renoprotective effects of adding angiotensin II receptor blocker to maximal recommended doses of ACE inhibitor in diabetic nephropathy: a randomized double-blind crossover trial.
    Rossing K; Jacobsen P; Pietraszek L; Parving HH
    Diabetes Care; 2003 Aug; 26(8):2268-74. PubMed ID: 12882847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination therapy of angiotensin II receptor blocker and calcium channel blocker exerts pleiotropic therapeutic effects in addition to blood pressure lowering: amlodipine and candesartan trial in Yokohama (ACTY).
    Maeda A; Tamura K; Kanaoka T; Ohsawa M; Haku S; Azushima K; Dejima T; Wakui H; Yanagi M; Okano Y; Fujikawa T; Toya Y; Mizushima S; Tochikubo O; Umemura S
    Clin Exp Hypertens; 2012; 34(4):249-57. PubMed ID: 22571446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal dose of candesartan for renoprotection in type 2 diabetic patients with nephropathy: a double-blind randomized cross-over study.
    Rossing K; Christensen PK; Hansen BV; Carstensen B; Parving HH
    Diabetes Care; 2003 Jan; 26(1):150-5. PubMed ID: 12502672
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect.
    Viberti G; Wheeldon NM;
    Circulation; 2002 Aug; 106(6):672-8. PubMed ID: 12163426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ; Lewis JB
    Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy.
    Ogawa S; Takeuchi K; Mori T; Nako K; Tsubono Y; Ito S
    Hypertens Res; 2007 Apr; 30(4):325-34. PubMed ID: 17541211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative Efficacy and Safety of Antihypertensive Agents for Adult Diabetic Patients with Microalbuminuric Kidney Disease: A Network Meta-Analysis.
    Huang R; Feng Y; Wang Y; Qin X; Melgiri ND; Sun Y; Li X
    PLoS One; 2017; 12(1):e0168582. PubMed ID: 28045910
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of up-titration of candesartan versus candesartan plus amlodipine on kidney function in type 2 diabetic patients with albuminuria.
    Okura T; Kojima M; Machida H; Sugiyama M; Kato T; Komada T; Miyazaki T; Ninomiya T; Ichikawa T; Nakatani K; Watanabe Y; Dohi Y; Ito M; Kimura G
    J Hum Hypertens; 2012 Apr; 26(4):214-9. PubMed ID: 21412266
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of combination therapy of angiotensin-converting enzyme inhibitor plus calcium channel blocker on urinary albumin excretion in hypertensive microalbuminuric patients with type II diabetes.
    Shigihara T; Sato A; Hayashi K; Saruta T
    Hypertens Res; 2000 May; 23(3):219-26. PubMed ID: 10821130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual blockade of the renin-angiotensin system versus maximal recommended dose of ACE inhibition in diabetic nephropathy.
    Jacobsen P; Andersen S; Rossing K; Jensen BR; Parving HH
    Kidney Int; 2003 May; 63(5):1874-80. PubMed ID: 12675866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.
    Song JH; Cha SH; Lee HJ; Lee SW; Park GH; Lee SW; Kim MJ
    Nephrol Dial Transplant; 2006 Mar; 21(3):683-9. PubMed ID: 16330466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination of half doses of angiotensin type 1 receptor antagonist and angiotensin-converting enzyme inhibitor in diabetic nephropathy.
    Fujisawa T; Ikegami H; Ono M; Nishino M; Noso S; Kawabata Y; Ogihara T
    Am J Hypertens; 2005 Jan; 18(1):13-7. PubMed ID: 15691611
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and rationale of Japanese evaluation between Formula of Azelnidipine and amlodipine add on olmesartan to Get antialbuminuric effect study (J-FLAG) : evaluation of the antialbuminuric effects between calcium channel blocker with sympatholytic action in hypertensive patients with diabetes and albuminuria.
    Ando K; Haneda M; Ito S; Kashihara N; Node K; Nangaku M; Shimosawa T; Kishimoto J; Fujita T
    Cardiovasc Drugs Ther; 2011 Aug; 25(4):341-7. PubMed ID: 21637969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria.
    Abe M; Maruyama N; Okada K; Matsumoto S; Matsumoto K; Soma M
    Hypertens Res; 2011 Aug; 34(8):935-41. PubMed ID: 21654755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension.
    Poldermans D; Glazes R; Kargiannis S; Wernsing M; Kaczor J; Chiang YT; Yen J; Gamboa R; Fomina I
    Clin Ther; 2007 Feb; 29(2):279-89. PubMed ID: 17472820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of the angiotensin II type 1 receptor antagonist candesartan, compared with angiotensin-converting enzyme inhibitors, on the urinary excretion of albumin and type IV collagen in patients with diabetic nephropathy.
    Sato A; Tabata M; Hayashi K; Saruta T
    Clin Exp Nephrol; 2003 Sep; 7(3):215-20. PubMed ID: 14586718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Imarikiren in Patients with Type 2 Diabetes and Microalbuminuria: A Randomized, Controlled Trial.
    Ito S; Kagawa T; Saiki T; Shimizu K; Kuroda S; Sano Y; Umeda Y
    Clin J Am Soc Nephrol; 2019 Mar; 14(3):354-363. PubMed ID: 30755452
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.